Aclaris Therapeutics, which is developing a proprietary hydrogen peroxide treatment for common skin lesions, raised $55 million by offering 5 million shares at $11, below the range of $14 to $16. Aclaris Therapeutics plans to list on the Nasdaq under the symbol ACRS. Jefferies and Citi acted as lead managers on the deal.
